Intravitreal Bevacizumab (Avastin®) Versus Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The specific aims of the study are to test the following hypotheses:
- That there is a difference in change in visual acuity resulting from treatment with
intravitreal bevacizumab compared with dexamethasone implant in eyes with advanced
macular oedema
- That there is a difference in degree of resolution of macular oedema resulting from
treatment with intravitreal bevacizumab compared with dexamethasone implant in eyes with
advanced macular oedema
- That both intravitreal bevacizumab and dexamethasone implants have a manageable and
acceptable safety profile in eyes with diabetic macular oedema
Phase:
Phase 2
Details
Lead Sponsor:
University of Sydney
Collaborator:
National Health and Medical Research Council, Australia